Home / Investors / Business development / LIAISON QuantiFERON®-TB Gold Plus assay co-development with QIAGEN

LIAISON QuantiFERON®-TB Gold Plus assay co-development with QIAGEN

How it works

Co-development of the new CLIA release of QuantiFERON®-TB Gold Plus diagnostic test available on the LIAISON family platforms.

Category
New products co-development
Technology
Immunodiagnostics
pdfPress release483.2KB

Carlo Rosa

CEO

I’m really excited about this market opportunity that sees DiaSorin joining forces with QIAGEN as a leading global provider of molecular testing solutions. This collaboration creates the opportunity to add unique and differentiating content to the broad assay menu of our flexible, efficient LIAISON analyzers. 

Rationale
Accellerate the conversion of the global latent TB testing market to the modern blood-based QuantiFERON® test. LIAISON QuantiFERON®-TB Gold Plus assay, now available in Europe, will be launched in the U.S. by 2019 and China by 2020.

Tuberculosis